WEST DES MOINES, IA--(NewMediaWire - Jun 8, 2015) - Spotlight
Innovation Inc. (OTCQB: STLT)
announces today that it completed the acquisition of a majority
ownership in Memcine Pharmaceuticals Inc., located at the
University of Iowa Research Park in Coralville, Iowa. Memcine
Pharmaceuticals is developing its Immunoplex™ vaccine platform
technology, which is designed to use the body's own naturally
occurring targeting system to deliver vaccine components to immune
cells and stimulate a robust response. Memcine Pharmaceuticals has
a licensing agreement for its technologies with the University of
Iowa.
Cris Grunewald, President and CEO of Spotlight Innovation, said,
"We are extremely pleased to be moving forward with Memcine
Pharmaceuticals' innovative team and technology. Memcine
Pharmaceuticals' Immunoplex technology has shown enormous potential
with broad applicability in both infectious diseases and oncology
immunotherapy. Memcine Pharmaceuticals' mission directly supports
Spotlight Innovation's goal of positively impacting the health and
well-being of as many people as possible, and we look forward to
furthering the development and fulfilling the promise of this
exciting, potentially life-saving technology."
Said Tony Vanden Bush, PhD, co-founder, co-inventor, Director
and Chief Scientific Officer of Memcine Pharmaceuticals, "We are
excited to be working with Spotlight Innovation to move the
Immunoplex platform technology through development and toward
clinical use for infectious disease prevention and personalized
cancer immunotherapeutics."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT)
specializes in identifying, acquiring and incubating companies
which have unique intellectual property (IP) in the medical sector.
The Company utilizes relationships with the nation's leading
academic and institutional IP developers to locate promising IP
technologies with potential for market share capture. With our
support, development, resources and strategic planning expertise,
we believe we can develop IP that will have a positive effect on
healthcare. We intend to partner with proven sector leaders on
commercialization once technologies are fully developed. Additional
information available at www.spotlightinnovation.com.
About Memcine Pharmaceuticals Inc.
Memcine Pharmaceuticals Inc. is an early-stage biotech company
focused on enhancing vaccine efficacy to improve human and animal
health globally. Memcine's Immunoplex™ technology platform uses the
body's naturally occurring targeting system to deliver vaccine
components. The current portfolio of potential infectious disease
vaccine targets includes influenza, HepB, and Ebola. Memcine
Pharmaceuticals has also conducted pre-clinical experiments in a
mouse model of breast cancer, where the vaccine technology showed
considerable promise as a therapeutic treatment. Additional
information available at www.memcine.com.
Forward Looking Statements
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.